Nasal Mucus Proteome and Immunotherapy

Launched by MEDICAL UNIVERSITY OF GRAZ · Jun 5, 2014

Keywords

ClinConnect Summary

This clinical trial is studying how nasal mucus, which acts as a defense barrier in our noses, changes in people with allergic rhinitis (a common allergy that causes symptoms like sneezing and a runny nose) compared to healthy individuals. Researchers want to see how these changes differ during pollen season (when allergies are often worse) and outside of it. They will also investigate how immunotherapy, a treatment that helps reduce allergy symptoms, affects the proteins in nasal mucus for those receiving the treatment. By analyzing the proteins in mucus, the researchers hope to identify patterns that could help understand how well immunotherapy works and find potential markers that indicate treatment success.

To participate in this trial, individuals aged 18 to 75 who have a confirmed pollen allergy and are eligible for immunotherapy can join. Participants will provide nasal mucus samples during two different times of the year (during and after pollen season) using a special device. They will be monitored to see how their mucus proteins change and how these changes relate to their treatment. However, those with chronic infections, poor overall health, or certain other conditions won’t be eligible to participate. This study could lead to new insights into allergic rhinitis and improve treatment options for those affected.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • pollen allergy verified by skin-prick test, blood tests for specific IgE (RAST) and allergic rhinitis symptoms, eligible for immunotherapy
• Exclusion Criteria:
• • chronic infectious diseases, bad overall health condition, pregnancy, long-term intake of nasal and/or systemic steroids or antihistamines, acute and/or chronic rhinosinusitis and parallel participation in other studies